ReviewInnovations in clinical neuroscience2020
CGRP Inhibitors for Migraine.
Review in Innovations in clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Migraine management in Saudi Arabia: An expert consensus.Neurosciences (Riyadh, Saudi Arabia) · 2025Guideline
- The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression.The journal of headache and pain · 2023Pooled it
- Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.Pain research & management · 2022Pooled it
- Targeting GCell reports. Medicine · 2026Article
- Bridging the gap: molecular mechanisms, regional activity and connectivity in headache disorders.Brain : a journal of neurology · 2026Review
- Pharmacists' Knowledge, Attitudes, and Practices Toward CGRP Inhibitors in Migraine Management: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- A Hybrid Digital-4E Strategy for comorbid migraine and depression: a medical hypothesis on an AI-driven, neuroadaptive, and exposome-aware approach.Frontiers in neurology · 2025Article
- Direct Comparison of Treatment Outcome Between the Botulinum Toxin and Calcitonin Gene-Related Peptide Monoclonal Antibody in Migraine Patients.Journal of clinical medicine research · 2024Article
- MetaCGRP is a high-precision meta-model for large-scale identification of CGRP inhibitors using multi-view information.Scientific reports · 2024Article
- Migraine and Stroke: A Scoping Review.Journal of clinical medicine · 2024Article
- Inhibition of Neurogenic Inflammatory Pathways Associated with the Reduction in Discogenic Back Pain.Asian spine journal · 2023Article
- Role of the Peripheral Nervous System in Skeletal Development and Regeneration: Controversies and Clinical Implications.Current osteoporosis reports · 2023Review
- Partners in Pain: New Insights into The Role of CGRP Signaling in Cross-Organ Sensitization.The Journal of pharmacology and experimental therapeutics · 2023Article
- Article
- Sex-specific metabolic profiling to explain the increased CVD risk in women with migraine: a narrative review.The journal of headache and pain · 2023Review
- New Insights into the Structure and Function of Class B1 GPCRs.Endocrine reviews · 2023Article
- Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care.British journal of pain · 2022Article
- Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults.Drugs in context · 2022Review
- Effects of Calcitonin-Gene-Related-Peptide on Auditory Nerve Activity.Frontiers in cell and developmental biology · 2021Article
- Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.Innovations in clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine headaches remain a significant medical concern; lots of people are adversely affected. Many existing pharmacotherapies have disappointing results. The pathophysiology is related to calcitonin gene-related peptide (CGRP) pathways. There is hope for better efficacy from the now-available CGRP inhibitor drugs made available to patients suffering these cephalgias.
Indexed as
Identifiers
32802591PMC7413335W3081503667What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.